Insulin Resistance – Pipeline Insight, 2026

DelveInsight’s “Insulin Resistance – Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies developing 20+ pipeline drugs in the Insulin Resistance pipeline landscape. It covers the Insulin Resistance pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Insulin Resistance treatment landscape. Learn more about the evolving Insulin Resistance pipeline today @ https://www.delveinsight.com/report-store/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Insulin Resistance Pipeline Report

• In December 2025, Eli Lilly and Company reported encouraging topline findings from its Phase III TRIUMPH-4 study evaluating retatrutide, underscoring its potential to enhance insulin sensitivity through its triple-agonist mechanism of action.

• In September 2025, Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA) has approved mazdutide for metabolic conditions including insulin resistance.

• In June 2025, AdipoPharma’s PATAS, an innovative adipocyte-targeted, disease-modifying insulin sensitizer, was highlighted at the ADA 85th Annual Meeting, with clinical development anticipated in late 2025.

• DelveInsight’s Insulin Resistance Pipeline Insight report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Insulin Resistance treatment.

• The leading Insulin Resistance companies include Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., and others.

• Promising Insulin Resistance therapies include CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others.

Download for updates and the latest revolution in Insulin Resistance care @ Insulin Resistance Clinical Trials Assessment

Insulin Resistance Emerging Drugs Profile

• Retatrutide: Eli Lilly and Company

Retatrutide is a novel triple-agonist peptide that activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique mechanism of action enhances insulin sensitivity, promotes weight loss, and improves glycemic control. The drug works by targeting multiple metabolic pathways simultaneously, providing comprehensive metabolic regulation. In December 2025, Eli Lilly reported encouraging Phase III TRIUMPH-4 study results demonstrating significant improvements in insulin sensitivity. Retatrutide is currently being evaluated in Phase III clinical trials to treat insulin resistance and metabolic disorders.

• Visepegenatide (PB-119): PegBio

Visepegenatide (PB-119) is a long-acting GLP-1 receptor agonist designed to improve insulin sensitivity and glycemic control in patients with metabolic disorders. The drug employs PEGylation technology to extend its half-life, allowing for less frequent dosing while maintaining therapeutic efficacy. By activating GLP-1 receptors, it enhances insulin secretion in a glucose-dependent manner and suppresses glucagon release, thereby improving overall metabolic function. The drug is currently in clinical development for the treatment of insulin resistance.

• CRB-913: Corbus Pharmaceuticals Holdings, Inc.

CRB-913 is a novel therapeutic candidate targeting inflammatory pathways associated with insulin resistance. The compound modulates immune responses and metabolic signaling to enhance insulin sensitivity in peripheral tissues. The drug’s mechanism involves reducing chronic low-grade inflammation, which is a key driver of insulin resistance in metabolic syndrome and type 2 diabetes. CRB-913 is currently being evaluated in clinical trials for the treatment of insulin resistance and related metabolic conditions.

For more information on the Insulin Resistance Emerging Drugs Profile, download DelveInsight’s comprehensive Insulin Resistance Pipeline Insight report.

The Insulin Resistance Pipeline Report Provides

• Detailed insights about companies developing therapies for Insulin Resistance, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Insulin Resistance treatment.

• Insulin Resistance companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Insulin Resistance drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Insulin Resistance market.

Learn more about Insulin Resistance Drugs opportunities in our comprehensive Insulin Resistance pipeline report @ Insulin Resistance Unmet Needs

Insulin Resistance Companies

There are 20+ key companies, such as Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, Trigemina Inc, and others, developing therapies for Insulin Resistance, with Eli Lilly and Company having its Insulin Resistance drug candidate in the most advanced Phase III stage.

DelveInsight’s Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

Insulin Resistance products have been categorized under various Molecule types such as:

• Small molecule

• Cell Therapy

• Peptides

• Polymer

• Small molecule

• Gene therapy

Discover the latest advancements in Insulin Resistance treatment by visiting our website. Stay informed @ Insulin Resistance Market Drivers and Barriers, and Future Perspectives

Scope of the Insulin Resistance Pipeline Report

• Coverage: Global

• Insulin Resistance companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., and others

• Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others.

• Insulin Resistance Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Insulin Resistance Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Insulin Resistance: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Insulin Resistance – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Insulin Resistance Key Companies

13. Insulin Resistance Key Products

14. Insulin Resistance Unmet Needs

15. Insulin Resistance Market Drivers and Barriers

16. Insulin Resistance Future Perspectives and Conclusion

17. Insulin Resistance Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services